Australia markets close in 5 hours 51 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.54-0.50 (-1.92%)
At close: 04:00PM EDT
25.54 0.00 (0.00%)
After hours: 04:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.65B
Enterprise value 2.28B
Trailing P/E 26.28
Forward P/E 21.37
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.53
Price/book (mrq)5.98
Enterprise value/revenue 5.81
Enterprise value/EBITDA 16.98

Trading information

Stock price history

Beta (5Y monthly) 0.56
52-week change 332.32%
S&P500 52-week change 3-13.66%
52-week high 329.93
52-week low 315.83
50-day moving average 326.82
200-day moving average 323.02

Share statistics

Avg vol (3-month) 3616.61k
Avg vol (10-day) 3579.83k
Shares outstanding 5107.11M
Implied shares outstanding 6N/A
Float 887.44M
% held by insiders 111.16%
% held by institutions 180.79%
Shares short (30 Aug 2022) 417.35M
Short ratio (30 Aug 2022) 429.25
Short % of float (30 Aug 2022) 425.02%
Short % of shares outstanding (30 Aug 2022) 416.20%
Shares short (prior month 28 July 2022) 417.93M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022


Profit margin 28.76%
Operating margin (ttm)33.44%

Management effectiveness

Return on assets (ttm)15.39%
Return on equity (ttm)23.36%

Income statement

Revenue (ttm)392.03M
Revenue per share (ttm)3.55
Quarterly revenue growth (yoy)12.90%
Gross profit (ttm)360.7M
EBITDA 132.06M
Net income avi to common (ttm)112.72M
Diluted EPS (ttm)0.94
Quarterly earnings growth (yoy)3.40%

Balance sheet

Total cash (mrq)370.09M
Total cash per share (mrq)3.45
Total debt (mrq)2.26M
Total debt/equity (mrq)0.51
Current ratio (mrq)8.54
Book value per share (mrq)4.15

Cash flow statement

Operating cash flow (ttm)151.42M
Levered free cash flow (ttm)123.13M